Resumes
Resumes
David Mold Phones & Addresses
-
Parkton, MD
-
Terra Alta, WV
-
Baltimore, MD
-
800 Stoneleigh Rd, Baltimore, MD 21212 (410) 377-2208
Work
Position:
Precision Production Occupations
Education
Degree:
Associate degree or higher
Business Records
Name / Title
Company / Classification
Phones & Addresses
Owner
David Mold
Spcl Diestlsfxtrs
Spcl Diestlsfxtrs
800 Stoneleigh Rd, Baltimore, MD 21212
Publications
Us Patents
Methods And Compositions For Delivery Of Catecholic Butanes For Treatment Of Tumors
View pageUS Patent:
20060141025, Jun 29, 2006
Filed:
Nov 21, 2005
Appl. No.:
11/284111
Inventors:
Ru Huang - Baltimore MD, US
Richard Park - Ithaca NY, US
Chih-Chuan Chang - Baltimore MD, US
Yu-Chuan Liang - Baltimore MD, US
David Mold - Baltimore MD, US
Elaine Lin - New York NY, US
Jonathan Heller - Raleigh NC, US
Neil Frazer - Cary NC, US
Richard Park - Ithaca NY, US
Chih-Chuan Chang - Baltimore MD, US
Yu-Chuan Liang - Baltimore MD, US
David Mold - Baltimore MD, US
Elaine Lin - New York NY, US
Jonathan Heller - Raleigh NC, US
Neil Frazer - Cary NC, US
International Classification:
A61K 9/48
A61K 31/24
A61K 31/205
A61K 31/24
A61K 31/205
US Classification:
424451000, 514554000, 514540000
Abstract:
The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.
Use Of Nordihydroguaiaretic Acid Derivatives In The Treatment Of Drug Resistant Cancer, Viral And Microbial Infection
View pageUS Patent:
20080207532, Aug 28, 2008
Filed:
Oct 6, 2005
Appl. No.:
11/664875
Inventors:
Ru Chih Huang - Baltimore MD, US
Jih Ru Hwu - Hsinchu, TW
Ming-Hua Hsu - Hsinchu, TW
David E. Mold - Baltimore MD, US
Yuan C. Lee - Baltimore MD, US
Chih-Chuan Chang - Baltimore MD, US
Jih Ru Hwu - Hsinchu, TW
Ming-Hua Hsu - Hsinchu, TW
David E. Mold - Baltimore MD, US
Yuan C. Lee - Baltimore MD, US
Chih-Chuan Chang - Baltimore MD, US
Assignee:
Johns Hopkins University - Baltimore MD
International Classification:
A61K 31/7034
C12N 5/06
C07H 15/04
C12Q 1/02
A61P 35/00
A61P 31/00
C12N 5/06
C07H 15/04
C12Q 1/02
A61P 35/00
A61P 31/00
US Classification:
514 25, 435375, 536 41, 435 29
Abstract:
Compositions and methods for using nordihydroguaiaretic acid (NDGA) derivatives for preventing the expression of MDR-1 gene and the synthesis of PgP protein or reversing multiple drug resistance in cells, and for using NDGA derivatives in combination with additional chemotherapeutic agents to treat drug resistant cancer and infections.
Methods And Compositions For Delivery Of Catecholic Butanes For Treatment Of Tumors
View pageUS Patent:
20110135711, Jun 9, 2011
Filed:
May 31, 2010
Appl. No.:
12/790894
Inventors:
Ru Chih C. Huang - Baltimore MD, US
Richard Park - Ithaca NY, US
Chih-Chuan Chang - Baltimore MD, US
Yu-Chuan Liang - Baltimore MD, US
David Mold - Baltimore MD, US
Elaine Lin - New York NY, US
Jonathan Heller - Raleigh NC, US
Neil Frazer - Cary NC, US
Richard Park - Ithaca NY, US
Chih-Chuan Chang - Baltimore MD, US
Yu-Chuan Liang - Baltimore MD, US
David Mold - Baltimore MD, US
Elaine Lin - New York NY, US
Jonathan Heller - Raleigh NC, US
Neil Frazer - Cary NC, US
International Classification:
A61K 31/225
A61K 31/05
A61K 9/127
A61K 31/09
A61K 31/222
A61P 35/00
A61P 29/00
A61P 31/18
A61K 31/05
A61K 9/127
A61K 31/09
A61K 31/222
A61P 35/00
A61P 29/00
A61P 31/18
US Classification:
424450, 514734, 514721, 514547, 514551
Abstract:
The present invention provides kits, methods and compositions for the treatment of diseases such as cancers. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.
Formulations Of Terameprocol And Temozolomide And Their Use In Stimulation Of Humoral Immunity In Tumors
View pageUS Patent:
20220409552, Dec 29, 2022
Filed:
Nov 25, 2020
Appl. No.:
17/779048
Inventors:
- Baltimore MD, US
- Taipei, TW
- Hsinchu City, TW
Yu-Chuan LIang - Taipei, TW
Kuang-Wen Liao - Hsinchu City, TW
Tiffany Jackson - Baltimore MD, US
David Mold - Baltimore MD, US
Chien-Hsien Lai - Baltimore MD, US
- Taipei, TW
- Hsinchu City, TW
Yu-Chuan LIang - Taipei, TW
Kuang-Wen Liao - Hsinchu City, TW
Tiffany Jackson - Baltimore MD, US
David Mold - Baltimore MD, US
Chien-Hsien Lai - Baltimore MD, US
International Classification:
A61K 31/05
A61K 31/09
A61K 31/444
A61K 31/495
A61P 35/00
A61K 47/22
A61K 47/14
A61K 9/00
A61K 31/09
A61K 31/444
A61K 31/495
A61P 35/00
A61K 47/22
A61K 47/14
A61K 9/00
Abstract:
The present invention provides novel pharmaceutical formulations comprising derivatives of NDGA, including MN (tetra-0-methyl nordihydroguaiaretic acid) and temozolomide and their use in the inhibition and treatment of neoplastic diseases, including glioblastoma multiforme, lung and other cancers.
Compositions Comprising Ndga Derivatives And Sorafenib And Their Use In Treatment Of Cancer
View pageUS Patent:
20150018302, Jan 15, 2015
Filed:
Feb 4, 2013
Appl. No.:
14/374323
Inventors:
- Baltimore MD, US
David Mold - Baltimore MD, US
Christopher Ruland - Annapolis MD, US
Yu-Chuan Liang - Baltimore MD, US
Jong Ho Chun - Woodbine MD, US
David Mold - Baltimore MD, US
Christopher Ruland - Annapolis MD, US
Yu-Chuan Liang - Baltimore MD, US
Jong Ho Chun - Woodbine MD, US
International Classification:
A61K 31/7016
A61K 31/05
A61K 31/09
A61K 31/44
A61K 31/05
A61K 31/09
A61K 31/44
US Classification:
514 53, 514346
Abstract:
The present invention provides pharmaceutical compositions comprising derivatives of NDGA, including M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib and their use in the inhibition and treatment of neoplastic diseases, such as liver cancer, colon cancer, breast cancer, brain cancers and ovarian cancers, for example, in a subject. Compositions comprising derivatives of NDGA, including M4N, sorafenib and additional therapeutic agents are also provided.
Conjugates Of Nitroimidazoles And Their Use As Chemotherapeutic Agents
View pageUS Patent:
20140186266, Jul 3, 2014
Filed:
May 30, 2012
Appl. No.:
14/122312
Inventors:
Ru Chih C. Huang - Baltimore MD, US
David Edward Mold - Baltimore MD, US
Jih Ru Hwu - Hsinchu, CN
Ming Hua Hsu - Tucheng, CN
Szu Chun Wu - Hsinchu, CN
David Edward Mold - Baltimore MD, US
Jih Ru Hwu - Hsinchu, CN
Ming Hua Hsu - Tucheng, CN
Szu Chun Wu - Hsinchu, CN
Assignee:
The John Hopkins University - Baltimore MD
International Classification:
A61K 31/4164
C07D 233/91
A61K 45/06
C07D 233/94
C07D 233/91
A61K 45/06
C07D 233/94
US Classification:
424 91, 5483301, 514398, 5483275
Abstract:
Novel compounds which are derivatives of tetra-O-methyl nordihydroguaiaretic acid (NDGA), as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof are provided. These NDGA derivatives have a nitroimidazole moiety and these derivatives show preferential toxicity to hypoxic cells as hypoxic cytotoxins. Their cytotoxicity toward hypoxic cells is a result of abstraction of hydrogen from target molecules by free radicals formed in the reduction of the nitro group. This makes the disclosed compounds an effective anti cancer drug because hypoxic cells are generally considered to be more resistant to anti cancer drugs than normal cells. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including hepatocellular carcinoma, breast cancer and prostate cancer, are also provided.